Induction of aggrecanase 1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced proteinPRATTA, Michael A; SCHERLE, Peggy A; GENGJIE YANG et al.Arthritis and rheumatism. 2003, Vol 48, Num 1, pp 119-133, issn 0004-3591, 15 p.Article

A new synthesis of cytoxazone and its diastereomers provides key initial sar informationCARTER, Percy H; LAPORTE, Jacob R; SCHERLE, Peggy A et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 7, pp 1237-1239, issn 0960-894X, 3 p.Article

Discovery of Disubstituted Cyclohexanes as a New Class of CC Chemokine Receptor 2 AntagonistsCHERNEY, Robert J; RUOWEI MO; SOLOMON, Kimberly A et al.Journal of medicinal chemistry (Print). 2008, Vol 51, Num 4, pp 721-724, issn 0022-2623, 4 p.Article

Benzimidazoles as benzamide replacements within cyclohexane-based CC chemokine receptor 2 (CCR2) antagonistsCHERNEY, Robert J; MO, Ruowei; ELLEN CVIJIC, Mary et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 19, pp 6181-6184, issn 0960-894X, 4 p.Article

Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2)CARTER, Percy H; BROWN, Gregory D; DECICCO, Carl P et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 19, pp 5455-5461, issn 0960-894X, 7 p.Article

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasmsQUINTAS-CARDAMA, Alfonso; VADDI, Kris; RUPAR, Mark et al.Blood. 2010, Vol 115, Num 15, pp 3109-3117, issn 0006-4971, 9 p.Article

Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonistsCHERNEY, Robert J; RUOWEI MO; DECICCO, Carl P et al.Bioorganic & medicinal chemistry letters (Print). 2009, Vol 19, Num 13, pp 3418-3422, issn 0960-894X, 5 p.Article

Beyond U0126. Dianion chemistry leading to the rapid synthesis of a series of potent MEK inhibitorsWITYAK, John; HOBBS, Frank W; SCHERLE, Peggy A et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 6, pp 1483-1486, issn 0960-894X, 4 p.Article

Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backboneCARTER, Percy H; BROWN, Gregory D; SCHERLE, Peggy A et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 9, pp 3311-3316, issn 0960-894X, 6 p.Article

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemiaEGHTEDAR, Alireza; VERSTOVSEK, Srdan; SCHERLE, Peggy A et al.Blood. 2012, Vol 119, Num 20, pp 4614-4618, issn 0006-4971, 5 p.Article

Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancerFRIDMAN, Jordan S; CAULDER, Eian; GRANDIS, Jennifer R et al.Clinical cancer research. 2007, Vol 13, Num 6, pp 1892-1902, issn 1078-0432, 11 p.Article

Both 5-arylidene-2-thioxodihydropyrimidine-4,6(1H, 5H)-diones and 3-thioxo-2,3-dihydro-1H-imidazo[1,5-a]indol-1-ones are light-dependent tumor necrosis factor-α antagonistsVOSS, Matthew E; CARTER, Percy H; STRZEMIENSKI, Paul et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 3, pp 533-538, issn 0960-894X, 6 p.Article